DK2147122T3 - Enzymatisk kræftbehandling - Google Patents

Enzymatisk kræftbehandling

Info

Publication number
DK2147122T3
DK2147122T3 DK08754910.1T DK08754910T DK2147122T3 DK 2147122 T3 DK2147122 T3 DK 2147122T3 DK 08754910 T DK08754910 T DK 08754910T DK 2147122 T3 DK2147122 T3 DK 2147122T3
Authority
DK
Denmark
Prior art keywords
enzymatic
cancer treatment
cancer
treatment
enzymatic cancer
Prior art date
Application number
DK08754910.1T
Other languages
English (en)
Inventor
David R Filpula
Puja Sapra
Original Assignee
Sigma Tau Rare Diseases S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Rare Diseases S A filed Critical Sigma Tau Rare Diseases S A
Application granted granted Critical
Publication of DK2147122T3 publication Critical patent/DK2147122T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK08754910.1T 2007-04-20 2008-04-18 Enzymatisk kræftbehandling DK2147122T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91303907P 2007-04-20 2007-04-20
PCT/US2008/060733 WO2008131163A1 (en) 2007-04-20 2008-04-18 Enzymatic anticancer therapy

Publications (1)

Publication Number Publication Date
DK2147122T3 true DK2147122T3 (da) 2014-10-13

Family

ID=39875909

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08754910.1T DK2147122T3 (da) 2007-04-20 2008-04-18 Enzymatisk kræftbehandling

Country Status (19)

Country Link
US (1) US8741283B2 (da)
EP (1) EP2147122B1 (da)
JP (1) JP5595904B2 (da)
KR (1) KR101540296B1 (da)
CN (1) CN101680039B (da)
BR (1) BRPI0810384B8 (da)
CA (1) CA2684749C (da)
CY (1) CY1117000T1 (da)
DK (1) DK2147122T3 (da)
ES (1) ES2507508T3 (da)
HR (1) HRP20140947T1 (da)
IL (1) IL201593A (da)
MX (1) MX2009011320A (da)
NZ (1) NZ580980A (da)
PL (1) PL2147122T3 (da)
PT (1) PT2147122E (da)
SI (1) SI2147122T1 (da)
TW (1) TWI486169B (da)
WO (1) WO2008131163A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2850323A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
ES2569940T3 (es) 2007-04-20 2016-05-13 Sigma-Tau Rare Disease Ltd Adenosina desaminasa recombinante estable
SG10201600836PA (en) * 2011-02-03 2016-03-30 Mirna Therapeutics Inc Synthetic mimics of mir-34
CA2964317C (en) 2014-10-14 2021-10-05 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
US10874724B2 (en) * 2015-05-22 2020-12-29 University Of Houston System Enzymatic immunomodulation of solid tumors and uses thereof
EP3426299A4 (en) * 2016-03-11 2019-10-16 University of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR TREATMENT OF TUMORS
CN110996975A (zh) 2017-04-13 2020-04-10 森迪生物科学公司 组合癌症免疫疗法
TW202035685A (zh) 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
WO2023086931A2 (en) * 2021-11-12 2023-05-19 Georgia Tech Research Corporation Adenosine deaminase 1 compositions and methods for using same

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346823A (en) * 1984-05-29 1994-09-13 Genencor, Inc. Subtilisin modifications to enhance oxidative stability
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US6180095B1 (en) * 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (en) * 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6251382B1 (en) * 1998-04-17 2001-06-26 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6824766B2 (en) * 1998-04-17 2004-11-30 Enzon, Inc. Biodegradable high molecular weight polymeric linkers and their conjugates
US6333396B1 (en) * 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
US20020088017A1 (en) * 1999-04-28 2002-07-04 Board Of Regents, The University Of Texas System Adenosine deaminase deficient transgenic mice and methods for the use thereof
US6579857B1 (en) * 1999-06-11 2003-06-17 Evanston Northwestern Healthcare Research Institute Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
US20030009017A1 (en) * 2000-11-08 2003-01-09 Leiby Kevin R. 38650, 28472, 5495, 65507, 81588 and 14354 methods and compositions of human proteins and uses thereof
US20040105839A1 (en) 2001-11-28 2004-06-03 Myung-Ok Park Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
CA2470104C (en) 2001-12-12 2015-01-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20040175804A1 (en) * 2003-03-04 2004-09-09 Skonezny Paul M. Process for preparing dideoxyinosine using adenosine deaminase enzyme
US7301003B2 (en) * 2005-08-26 2007-11-27 Enzon Pharmaceuticals, Inc. Method of preparing polymers having terminal amine groups
US7601798B2 (en) * 2005-10-04 2009-10-13 Enzon Pharmaceuticals, Inc. Methods of preparing polymers having terminal amine groups using protected amine salts
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
CA2653061A1 (en) 2006-06-21 2007-12-27 Enzon Pharmaceuticals, Inc. Stabilized proteins
CN101534861B (zh) 2006-09-15 2013-10-02 安佐制药股份有限公司 具有基于位阻酯的生物可降解连接基的聚环氧烷
CA2671209A1 (en) * 2006-12-29 2008-07-10 Enzon Pharmaceuticals, Inc. Use of adenosine deaminase for treating pulmonary disease
ES2569940T3 (es) 2007-04-20 2016-05-13 Sigma-Tau Rare Disease Ltd Adenosina desaminasa recombinante estable

Also Published As

Publication number Publication date
PL2147122T3 (pl) 2015-05-29
US20090047270A1 (en) 2009-02-19
PT2147122E (pt) 2014-10-15
EP2147122A1 (en) 2010-01-27
IL201593A (en) 2017-07-31
JP5595904B2 (ja) 2014-09-24
WO2008131163A1 (en) 2008-10-30
TWI486169B (zh) 2015-06-01
TW200902051A (en) 2009-01-16
KR20090130108A (ko) 2009-12-17
WO2008131163A8 (en) 2010-01-28
EP2147122B1 (en) 2014-07-16
BRPI0810384B8 (pt) 2021-05-25
US8741283B2 (en) 2014-06-03
CN101680039A (zh) 2010-03-24
HRP20140947T1 (hr) 2015-02-13
EP2147122A4 (en) 2010-11-17
IL201593A0 (en) 2010-05-31
CA2684749C (en) 2016-06-21
JP2010524968A (ja) 2010-07-22
BRPI0810384A2 (pt) 2014-11-04
AU2008242791A1 (en) 2008-10-30
SI2147122T1 (sl) 2015-01-30
CA2684749A1 (en) 2008-10-30
KR101540296B1 (ko) 2015-07-31
CN101680039B (zh) 2016-08-24
CY1117000T1 (el) 2017-04-05
MX2009011320A (es) 2009-12-15
NZ580980A (en) 2012-04-27
RU2009142817A (ru) 2011-05-27
BRPI0810384B1 (pt) 2021-02-02
ES2507508T3 (es) 2014-10-15

Similar Documents

Publication Publication Date Title
BRPI0810206A2 (pt) Método de tratar câncer
BR112012005594A2 (pt) tratamento de câncer
DK2121139T3 (da) Formulations for cancer treatment
BRPI0818320A2 (pt) composição para tratamento de câncer de próstata (pca)
BRPI0910854A2 (pt) métodos de tratamento
ZA200807934B (en) Cancer treatments
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
DK2147122T3 (da) Enzymatisk kræftbehandling
BR112012002797A2 (pt) tratamento de câncer de próstata
EP2310006A4 (en) TREATMENT OF CANCER
DK2219683T3 (da) Målrettet radioterapi
DE602008004368D1 (de) Endoskop-Behandlungswerkzeug
DK2173831T3 (da) Brøndbehandling
BRPI0821652A2 (pt) tratamento de biocombustíveis
DK2330887T3 (da) Behandlingsindretning
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
DE502008000740D1 (de) Rollosystem
BRPI0813789A2 (pt) Potenciação de quimioterapia contra câncer
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
DE602008000310D1 (de) Endoskopisches Behandlungswerkzeug
BRPI0920743A2 (pt) ribonucleases terapeuticas
BRPI0818598A2 (pt) agentes terapêuticos - 802
DE602008006133D1 (de) Endoskopisches Behandlungswerkzeug
GB0804496D0 (en) Treating cancer